Cyclo Therapeutics, Inc.
CYTH · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.04 | 0.03 | 0.04 |
| FCF Yield | -62.35% | -126.25% | -63.25% | -123.53% |
| EV / EBITDA | -0.89 | -0.67 | -0.51 | 0.64 |
| Quality | ||||
| ROIC | -346.28% | -2,101.83% | -90.18% | -83.98% |
| Gross Margin | 90.85% | 89.90% | 90.16% | 92.65% |
| Cash Conversion Ratio | 0.81 | 0.98 | 1.05 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.12% | 15.05% | 16.33% | -3.70% |
| Free Cash Flow Growth | -6.99% | -0.68% | -74.88% | -30.38% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.10 | 1.15 | 1.41 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 0.55 | 0.69 | 0.28 |
| Cash Conversion Cycle | -17,019.53 | -5,185.78 | -7,945.16 | -18,112.66 |